spread
antibioticresist
pathogen
increas
potenti
catastroph
consequ
emerg
clinic
signific
resist
occur
within
year
deploy
new
antibiot
estim
hospitalacquir
infect
resist
one
current
antibiot
treatment
infect
signific
impact
treatment
failur
longer
hospit
stay
health
care
cost
signific
number
newli
develop
antibiot
repres
minor
alter
wellknown
chemic
scaffold
therefor
particularli
prone
resist
relentless
increas
number
resist
pathogen
threaten
year
medic
advanc
wwwadvancedsciencenewscom
wwwadvhealthmatd
np
small
enough
penetr
anatom
cellular
barrier
addit
produc
minim
toxic
aspir
decreas
emerg
drugresist
strain
microorgan
produc
np
low
cost
largescal
level
necessari
commerci
viabil
particularli
lessdevelop
countri
summari
trait
ideal
antimicrobi
np
carrier
includ
drug
protect
degrad
improv
bioavail
control
releas
sustain
concentr
specif
target
diseas
site
overcom
anatom
cellular
barrier
minim
toxic
decreas
emerg
drugresist
low
cost
scalabl
product
purpos
review
summar
publish
work
antimicrobi
np
therapeut
potenti
combat
resist
pathogen
increas
emerg
mutat
strain
microb
recent
discov
coronaviru
coat
face
mask
np
may
use
prevent
measur
health
care
worker
civilian
studi
carri
li
et
al
ten
treat
untreat
mask
mixtur
ag
np
tio
np
test
e
coli
aureu
growth
report
treat
mask
h
incub
untreat
mask
show
increas
bacteri
number
wound
dress
anoth
import
area
investig
bacteri
cellulos
fiber
possess
antimicrobi
activ
howev
upon
incorpor
ag
np
fiber
exhibit
strong
antimicrobi
respons
e
coli
aureu
np
proven
overcom
shortcom
exist
antibiot
includ
rel
short
halfliv
low
bioavail
possibl
toxic
side
effect
exampl
gentamicin
previous
studi
differ
np
drug
deliveri
system
poli
lactidecoglycolid
plga
chitosan
observ
np
carri
gentamicin
aid
drug
deliveri
specif
site
sustain
releas
drug
addit
encapsul
antibiot
within
np
observ
reduc
toxic
side
effect
rel
convent
administr
zibiao
li
obtain
phd
nation
univers
singapor
nu
current
work
research
scientist
imr
star
singapor
research
interest
focus
biodegrad
function
polymer
materi
design
structureproperti
correl
formul
healthcar
consum
care
applic
xian
jun
loh
head
soft
materi
depart
institut
materi
research
engin
imr
star
assist
professor
nation
univers
singapor
nu
main
research
interest
design
supramolecular
stimulirespons
polym
hydrogel
biomed
person
care
applic
antimicrobi
nanoparticl
classifi
metal
nanoparticl
nonmetal
nanoparticl
includ
poli
meric
nanoparticl
lipidbas
nanoparticl
adv
healthcar
mater
metal
nanoparticl
includ
silver
gold
copper
report
kill
differ
type
bacteria
nanomet
specif
properti
mechan
action
gener
antimicrobi
mechan
nanomet
propos
involv
disrupt
cell
membran
metabol
metal
nanoparticl
may
penetr
cell
membran
disrupt
associ
enzym
lead
microbi
death
figur
moreov
metal
nanoparticl
gener
reactiv
oxygen
speci
ro
caus
dna
damag
bacteri
death
attach
nanoparticl
cell
membran
also
reduc
bacteri
replic
import
paramet
antimicrobi
np
includ
nanomet
dimens
shape
concentr
metal
investig
antibacteri
agent
silver
ag
np
perhap
prove
use
wide
spectrum
microorgan
silver
compound
possess
potent
bactericid
activ
develop
np
potenti
drug
treatment
antimicrobi
efficaci
silver
np
determin
size
shape
natur
cap
agent
linear
correl
observ
size
silver
np
minimum
inhibitori
concentr
gramposit
gramneg
strain
ag
np
shown
kill
yeast
disrupt
plasma
membran
thu
affect
membran
potenti
cell
amphotericin
b
amb
use
posit
control
plasma
membran
dph
fluoresc
anisotropi
candida
albican
display
signific
decreas
concentr
ag
np
amb
increas
result
consist
disrupt
plasma
membran
ag
np
amb
studi
ag
np
exhibit
minimum
inhibitori
concentr
mic
ml
similar
exhibit
amb
ml
moreov
nanoag
caus
less
hemolysi
erythrocyt
lysi
compar
amb
lysi
concentr
ag
np
display
averag
mic
valu
ml
compar
ml
zno
np
ml
au
np
streptococcu
mutan
ag
np
also
found
possess
antivir
properti
may
prove
import
find
view
rise
number
virusrel
death
worldwid
virus
highli
adapt
abl
switch
new
host
overcom
antivir
mechan
million
peopl
newli
infect
human
immunodefici
viru
infect
hiv
bring
number
peopl
live
hiv
total
million
million
acquir
immunodefici
syndrom
aid
death
report
year
ag
np
viricid
cellfre
also
cellassoci
base
viral
infect
assay
np
appear
block
viral
entri
interact
preinfect
stage
anoth
studi
poli
pvp
coat
ag
np
investig
potenti
topic
vagin
microbicid
infect
cervic
tissu
expos
nonspermicid
gel
pvpcoat
ag
np
h
display
sign
toxic
min
pretreat
gel
prevent
transmiss
isol
min
treatment
follow
thorough
wash
drug
protect
tissu
infect
h
emerg
multidrugresist
mdr
bacteria
becom
major
threat
public
health
recent
studi
show
coat
au
nanoparticl
cation
hydrophob
function
group
could
suppress
growth
gramneg
gramposit
uropathogen
includ
mdr
pathogen
figur
result
reveal
surfac
chemistri
play
import
role
au
np
antimicrobi
activ
provid
ration
design
element
develop
new
antibiot
np
taken
togeth
high
biocompat
slow
develop
resist
gener
use
function
au
np
report
studi
provid
promis
approach
combat
mdr
infect
copper
nanoparticl
cu
np
also
exhibit
strong
abil
inhibit
microb
cu
np
easi
develop
ecofriendli
effect
pathogen
bacteria
alga
virus
demonstr
figur
propos
cu
np
act
wide
spectrum
bacteri
speci
interact
group
result
copyright
elsevi
wwwadvancedsciencenewscom
wwwadvhealthmatd
protein
denatur
also
exhibit
high
affin
amin
carboxyl
group
present
cell
membran
penetr
cu
np
disturb
structur
dna
crosslink
nucleic
acid
strand
also
result
bacteri
cell
death
tabl
summar
studi
metal
np
antimicrobi
mechan
action
metal
np
also
function
antimicrobi
surfac
molecul
advantag
np
includ
produc
longer
last
antimicrobi
effect
ensur
microb
encount
antimicrobi
drug
expos
high
surfac
concentr
silica
nanoparticl
snp
function
amb
exampl
snp
chosen
low
toxic
high
stabil
durabl
eas
modif
allow
incorpor
array
differ
function
molecul
snp
incorpor
dexoxamb
found
total
elimin
c
albican
amb
known
caus
degre
hemolysi
howev
immobil
signific
releas
hemoglobin
observ
studi
snp
function
amb
found
effect
c
albican
silver
nanoparticl
observ
silver
np
fungistat
concentr
observ
snp
function
amb
increas
effect
antimicrobi
molecul
tether
np
support
work
gajbhiy
et
al
fluconazol
display
increas
antifung
activ
presenc
ag
np
zone
inhibit
increas
time
test
c
albican
show
littl
differ
test
f
semitectum
p
herbarum
increas
area
howev
advers
biolog
effect
nanomateri
report
recent
year
one
studi
singlewal
carbon
nanotub
shown
produc
free
radic
result
oxid
stress
cellular
toxic
caus
loss
dermal
cell
viabil
h
carbon
nanotub
exposur
anoth
studi
report
tio
nanoparticl
surfac
water
may
risk
aquat
life
develop
research
necessari
determin
potenti
threat
np
may
pose
polymer
np
use
antimicrobi
drug
deliveri
structur
stabl
thu
synthes
narrow
size
distribut
ii
appropri
select
polym
length
surfact
organ
solvent
gener
precis
set
particl
properti
iii
function
group
surfac
schemat
represent
illustr
antimicrobi
activ
copper
nanoparticl
bacteria
fungi
virus
reproduc
permiss
copyright
springer
wwwadvancedsciencenewscom
wwwadvhealthmatd
polymer
np
chemic
modifi
effect
target
microb
polymer
np
includ
polylact
acid
pla
polyhydroxyalkano
pha
polydlglycolid
plg
plga
polycaprolacton
pcl
polycyanoacryl
pca
biodegrad
np
gener
clear
rapidli
blood
system
phagocyt
cell
therebi
minim
bioaccumul
associ
side
effect
henc
also
necessari
surfac
modif
escap
delay
phagocyt
clearanc
polymer
np
modifi
polyethylen
glycol
peg
improv
blood
circul
halflif
yuan
et
al
report
synthesi
antibacteri
properti
biodegrad
poli
ethylen
oxid
poli
poli
methacryl
peopclptbam
figur
studi
desir
triblock
copolym
synthes
twostep
reaction
process
includ
ring
open
polymer
rop
prepar
peopcl
diblock
copolym
follow
chain
extens
ptbam
via
atom
transfer
radic
polymer
atrp
presenc
hydrophob
pcl
segment
provid
drive
forc
copolym
selfassembl
micel
also
impart
biodegrad
wherea
pegyl
afford
better
biocompat
colloid
stabil
peopclptbam
micel
inher
antibacteri
membraneact
despit
absenc
quaternari
ammonium
group
presenc
secondari
amin
ptbam
block
cation
physiolog
condit
addit
util
ptbam
circumv
signific
hemolyt
effect
quaternari
ammoniumbas
antimicrobi
materi
antimicrobi
test
show
peopclptbam
copolym
highest
ptbam
content
exhibit
potent
importantli
optim
mic
valu
much
higher
critic
micel
concentr
cmc
indic
selfassembl
prerequisit
polym
exhibit
antimicrobi
efficaci
mani
research
also
demonstr
potenti
role
polymer
np
antimicrobi
drug
deliveri
plga
load
gentamicin
aminoglycosid
antibiot
use
treatment
pseudomonoa
infect
data
collect
studi
show
plga
nanoparticl
carri
gentamicin
perform
better
free
gentamicin
latter
reduc
p
aeruginosa
infect
h
level
infect
return
level
compar
salinetr
control
h
howev
antimicrobi
activ
remain
high
even
h
equal
concentr
gentamicinload
plga
nanoparticl
use
result
support
work
peng
et
al
investig
effect
free
voriconazol
versu
plga
np
load
voriconazol
found
plga
np
load
voriconazol
show
greater
potenc
vivo
extend
fungicid
time
free
voriconazol
vitro
research
microorgan
similarli
support
advantag
polymer
np
drug
deliveri
system
caval
et
al
investig
efficaci
antivir
np
load
acyclovir
acyclovir
use
treat
herp
simplex
viru
hsv
infect
howev
acyclovir
need
taken
oral
five
time
daili
due
short
halflif
h
low
bioavail
polymer
np
prepar
use
aacryloylmorpholin
monoconjug
free
acyclovir
acyclovirload
np
incub
vero
cell
separ
intracellular
drug
concentr
determin
found
intracellular
drug
concentr
much
higher
cell
incub
acyclovirload
np
cell
incub
free
acyclovir
likewis
hiv
proteas
inhibitor
saquinavir
nucleosid
analog
zalcitabin
load
polyhexycyanocryl
np
free
saquinavir
display
littl
antivir
activ
acut
infect
human
monocytesmacrophag
cell
saquinavirload
np
show
good
antivir
activ
howev
zalcitabin
load
np
appear
enhanc
antivir
activ
henc
appear
proteas
inhibitor
drug
may
gain
npload
nucleosid
analog
liposom
liposom
compos
bilay
membran
consist
amphipath
phospholipid
enclos
interior
space
research
intens
antimicrobi
drug
deliveri
anticanc
drug
doxil
produc
orthobiotech
use
treatment
aidsassoci
kaposi
sarcoma
becam
first
liposom
deliveri
system
approv
food
drug
administr
fda
liposom
exhibit
antimicrobi
properti
either
alon
encapsul
enhanc
antivir
efficaci
drug
bilay
membran
liposom
mimic
cell
membran
possess
abil
fuse
directli
microb
allow
drug
payload
liposom
adv
healthcar
mater
polydllactidecoglycolid
plga
gentamicin
p
aeruginosa
control
antibiot
releas
improv
antimicrobi
effect
polydlglycolid
plg
econazol
moxifloxacin
mycobacterium
tuberculosi
prolong
therapeut
drug
level
decreas
dosag
frequenc
polyethylen
glycol
peg
pla
halofantrin
plasmodiumbergh
extend
blood
circul
halflif
algin
rifampicin
pyrazinamid
mycobacterium
tuberculosi
protect
drug
control
drug
releas
improv
antimicrobi
effect
antifung
poloxam
coat
poli
epsiloncaprolacton
amphotericin
b
candida
albican
decreas
toxic
via
reduc
accumul
liver
kidney
antivir
aacryloylmorpholin
acyclovir
improv
antivir
activ
polyhexycyanocryl
saquinavir
hiv
improv
deliveri
antivir
figur
liposom
effici
carrier
drug
deliveri
reproduc
permiss
copyright
hindawi
wwwadvancedsciencenewscom
wwwadvhealthmatd
releas
microb
addit
liposom
surfac
easili
modifi
enhanc
vivo
stabil
target
ligand
enabl
specif
drug
deliveri
figur
peg
commonli
use
liposom
surfac
creat
protect
layer
increas
blood
circul
halflif
polyunsatur
er
liposom
perl
significantli
reduc
viral
secret
infect
treatment
hbv
hcv
hiv
infect
act
reduct
cholesterol
essenti
viru
infect
mareuil
et
al
compar
antivir
efficaci
synthet
polymer
peptid
encapsul
liposom
rel
free
liposom
encapsul
exhibit
greater
antivir
efficaci
ten
fivefold
hivinfect
tcell
human
peripher
blood
lymphotcyt
pbl
respect
egg
phosphatidylcholin
egg
cholesterol
tocopherol
increas
antivir
efficaci
stearylamin
sa
dicetylphosph
zidovudin
hiv
improv
target
wwwadvancedsciencenewscom
wwwadvhealthmatd
room
temperatur
encompass
solid
lipid
core
drug
mobil
lower
solid
lipid
state
compar
lipid
oili
phase
allow
better
control
releas
drug
surfact
use
emulsif
enhanc
sln
stabil
sln
use
cosmet
pharmaceut
product
skin
care
industri
sln
found
occlus
excipi
form
thin
film
appli
skin
reduc
evapor
help
retain
skin
moistur
enhanc
molecul
penetr
anoth
advantag
sln
stabil
water
dermal
cream
make
easier
incorpor
cosmet
skin
care
product
sln
use
topic
small
size
prolong
drug
resid
time
skin
aid
drug
penetr
skin
found
sln
load
econazol
nitrat
particl
diamet
nm
show
increas
drug
diffus
rate
deeper
skin
layer
support
studi
lv
et
al
report
twofold
increas
increas
cumul
amount
penciclovir
penetr
excis
rat
skin
penciclovirload
sln
rel
penetr
commerci
cream
control
h
administr
improv
drug
target
specif
site
especi
use
drug
deliveri
central
nervou
system
cn
bloodbrain
barrier
bbb
bloodcerebrospin
fluid
barrier
obstruct
effect
transport
drug
sln
may
provid
solut
problem
chattopadhyay
et
al
show
higher
drug
uptak
human
brain
endotheli
cell
repres
bbb
vitro
atazanavir
deliv
via
sln
sln
use
oral
administr
produc
powder
form
pellet
capsul
tablet
tobramycinload
sln
display
greater
effect
pseudomona
aeruginosa
infect
gastrointestin
tract
patient
cystic
fibrosi
sln
consist
natur
compon
requir
highpressur
homogen
sophist
machineri
therebi
allow
largescal
inexpens
manufactur
howev
sln
formul
may
limit
unwant
burst
releas
drug
due
particl
growth
agglomer
coagul
nlc
encompass
imperfect
crystal
amorph
particl
allow
drug
load
molecular
form
cluster
aggreg
enhanc
drug
load
give
rise
less
pronounc
burst
releas
drug
reduc
proport
crystallin
structur
tabl
give
summari
lipidbas
np
antimicrobi
drug
deliveri
cai
et
al
report
new
lipid
polym
nanoparticl
formul
rhamnolipid
phospholipid
outer
mix
lipid
layer
rhlpclpn
figur
amoxicillin
amx
figur
design
strategi
lipid
polym
nanoparticl
erad
bacteri
biofilm
reproduc
permiss
copyright
elsevi
wwwadvancedsciencenewscom
wwwadvhealthmatd
pectin
sulfat
pec
load
lpn
facilit
disrupt
h
pylori
biofilm
enhanc
suscept
antibacteri
agent
studi
show
rhlpclpn
could
significantli
disrupt
h
pylori
biofilm
exert
stronger
potenc
control
nanoparticl
phospholipid
alon
outer
layer
addit
strategi
use
combin
pec
amoxicillin
exhibit
stronger
antimicrobi
activ
amoxicillin
alon
lower
inhibit
concentr
amoxicillinload
nanoparticl
biofilm
detect
demonstr
nanoparticl
could
reduc
infect
resist
importantli
rhlpclpn
could
also
provid
protect
ag
cell
h
pylori
infect
polymer
np
form
via
spontan
selfassembl
hydrophil
hydrophob
segment
diblock
copolym
polym
drug
first
dissolv
watermisc
organ
solvent
aceton
acetonitril
mixtur
ad
aqueou
solut
organ
solvent
evapor
polym
drug
undergo
nanoprecipit
via
rapid
solvent
diffus
produc
np
altern
polymer
np
prepar
linear
polym
via
emuls
polymer
method
monom
first
dissolv
polymer
media
surfact
follow
addit
polymer
initi
result
format
nanocapsul
antimicrobi
either
absorb
np
process
coval
attach
surfac
np
form
hydrophob
drug
typic
load
via
absorpt
hydrophil
drug
attach
via
coval
conjug
tabl
summar
report
method
prepar
polymer
np
differ
prepar
method
differ
composit
liposom
contribut
efficaci
antimicrobi
carrier
electrospray
produc
broad
array
np
techniqu
gener
monodispers
droplet
size
rang
nanomet
micromet
depend
process
paramet
electr
field
induc
free
charg
concentr
surfac
liquid
tend
affect
sensit
biomolecul
nucleic
acid
method
provid
better
control
high
drug
nucleic
acid
encapsul
effici
tabl
studi
wu
et
al
effect
antisens
oligodeoxynucleotid
odn
encapsul
lipoplex
gener
coaxial
electrospray
compar
produc
via
standard
ethanol
dilut
method
found
coaxial
electrospray
simpler
continu
onestep
method
requir
less
time
effort
produc
lipoplex
good
balanc
lipoplex
product
size
surfac
charg
achiev
adjust
process
paramet
lipoplex
produc
use
intraven
inject
aerosol
inhal
therapi
sln
nlc
produc
use
sever
method
summar
tabl
highpressur
homogen
hph
arguabl
effect
techniqu
yield
narrow
particl
size
distribut
avoid
use
organ
solvent
scalabl
howev
hph
involv
melt
lipid
high
energi
input
make
unsuit
temperatureand
mechan
sensit
biomolecul
wu
et
al
demonstr
electrospray
effici
method
produc
highli
monodispers
cholesterol
np
cholesterol
concentr
final
solut
ml
filtrat
time
higher
cholesterol
solubl
limit
normal
method
achiev
larg
antimicrobi
effect
simpli
increas
dosag
howev
high
dosag
increas
likelihood
cytotox
drug
resist
thu
new
strategi
specif
deliv
antimicrobi
agent
need
encapsul
one
best
strategi
passiv
target
exploit
enhanc
permeabl
retent
effect
drug
deliveri
interior
aqueou
space
within
liposom
allow
load
space
antimicrobi
polymyxin
b
exampl
effect
p
aeruginosa
use
treatment
pneumonia
chronic
bronchiopneumonia
cystic
fibrosi
usag
howev
limit
toxic
side
effect
toxic
reduc
encapsul
drug
liposom
addit
antimicrobi
activ
resist
strain
p
aeruginosa
found
adv
healthcar
mater
improv
polymyxin
bload
liposom
undergo
membran
fusion
p
aeruginosa
allow
high
dose
drug
deliv
bacteria
overwhelm
resist
efflux
mechan
bacteria
anoth
exampl
anticanc
drug
doxil
doxorubicinencapsul
peglyat
liposom
observ
better
drug
retent
circul
time
rel
free
doxorubicin
receptorbas
bind
activ
target
method
use
conjug
receptor
specif
ligand
site
specif
target
antimicrobi
conjug
cell
tissuespecif
ligand
allow
accumul
target
site
dehydrationrehydr
vesicl
egg
phosphatidylcholin
phosphatid
acid
pa
stearylamin
sa
distearoyl
phosphatidylcholin
dspc
cholesterol
reversephas
evapor
vesicl
ps
cholesterol
egg
phosphatidylcholin
epc
monohydr
pe
acid
disodium
salt
pa
dihexadecyl
hydrogen
phosphat
dp
diethyl
ether
isoton
buffer
freezethaw
multilamellar
vesicl
ps
cholesterol
egg
phosphatidylcholin
epc
monohydr
wwwadvancedsciencenewscom
wwwadvhealthmatd
possibl
nontarget
np
observ
support
result
kocbek
et
al
modifi
plga
np
monoclon
antibodi
mab
found
modifi
plga
np
show
enhanc
bind
target
cancer
cell
possibl
nontarget
np
sitespecif
target
via
receptor
allow
np
carri
therapeut
drug
reach
diseas
site
accur
rapidli
strategi
appli
antimicrobi
drug
liposom
contain
aminoglycosid
demonstr
direct
deliveri
antibiot
thu
enhanc
intraphagocyt
kill
bacteria
first
step
infect
adher
microorgan
epitheli
cell
research
gener
focus
effici
effect
drug
load
capac
np
subsequ
drug
deliveri
howev
use
chemotherapeut
agent
microorgan
unfortun
led
rise
resist
strain
prevent
infect
may
serv
altern
strategi
treatment
studi
conduct
mccarron
et
al
polymer
np
adsorb
onto
surfac
blastospor
therebi
significantli
reduc
adhes
buccal
epitheli
cell
bec
vitro
although
complet
inhibit
microbi
adher
achiev
extent
reduct
substanti
rel
untreat
blastospor
may
prove
use
prophylaxi
candidosi
oral
caviti
increas
antibiot
resist
becom
critic
issu
health
care
industri
respons
failur
convent
antimicrobi
therapi
metal
nanoparticl
display
potent
antimicrobi
activ
rapidtimekil
avoid
antibiot
resist
base
specif
properti
mechan
action
involv
disrupt
membran
metabol
membranerel
process
nonmetal
nanoparticl
includ
polym
lipidbas
nanoparticl
use
carrier
deliv
antimicrobi
drug
target
enhanc
efficaci
increas
payload
drug
reduc
cytotox
biocid
mechan
action
differ
class
nanoparticl
still
clear
mani
investig
ascrib
antibacteri
activ
either
oxid
stress
reactiv
oxygen
speci
ro
nanoparticl
eg
mgo
antibacteri
activ
may
relat
bacteri
metabol
thu
work
area
requir
quest
ration
antimicrobi
therapi
anoth
limit
current
research
lack
standard
differ
investig
employ
varieti
bacteri
strain
differ
reaction
time
use
vari
nanoparticl
formul
make
compar
antimicrobi
efficaci
difficult
likewis
research
employ
varieti
vivo
vitro
model
measur
antimicrobi
activ
mammalian
cytotox
draw
quit
differ
conclus
model
nevertheless
clear
nanoparticl
use
vaccin
drug
deliveri
system
either
appli
topic
access
specif
diseas
site
via
blood
circulatori
system
greater
effici
particl
engin
minim
cost
reduc
environment
harm
lead
improv
commerci
viabil
technolog
longterm
toxic
effect
np
remain
unknown
understand
mechan
np
function
crucial
avoid
possibl
advers
side
effect
cellular
level
halflif
np
bodi
also
fundament
knowledg
respect
